Top Markets
#1 Black Phoenix Black Phoenix +826.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#3 Beam Beam +24.88%
#4 Bless Bless +21.52%
#5 Tutorial Tutorial +21.07%
#6 SAFEcoin SAFEcoin +20.45%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.37%
#8 Magma Finance Magma Finance +17.16%
#9 THORChain THORChain +17.07%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.57%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062
Classifica tra le azioni #5801
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Prezzo delle azioni
$2.34
Capitalizzazione di mercato
$2.43B
Variazione (1 giorno)
-0.37%
Variazione (1 anno)
-14.62%
Paese
CN
Scambia China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Categoria

Healthcare
Margine operativo per China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di China Resources Double-Crane Pharmaceutical Co.,Ltd., il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per China Resources Double-Crane Pharmaceutical Co.,Ltd. da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.